<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02795117</url>
  </required_header>
  <id_info>
    <org_study_id>PRG-NY-15-013</org_study_id>
    <nct_id>NCT02795117</nct_id>
  </id_info>
  <brief_title>Comparative Safety and Efficacy of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Padagis LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Padagis LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and efficacy of Perrigo's product to an&#xD;
      FDA approved product for the treatment of inflammatory lesions rosacea&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2016</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Percent Change From Baseline in the Inflammatory (Papules and Pustules) Lesion Count</measure>
    <time_frame>Day 1 to Day 84</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjects With Clinical Success on the Investigator Global Assessment</measure>
    <time_frame>Day 1 to Day 84</time_frame>
    <description>Clinical success is defined as a score of clear or almost clear</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">486</enrollment>
  <condition>Rosacea</condition>
  <arm_group>
    <arm_group_label>Test product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference product</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo product</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivermectin</intervention_name>
    <arm_group_label>Test product</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivermectin (reference)</intervention_name>
    <arm_group_label>Reference product</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo product</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Must sign an Institutional Review Board (IRB) approved written informed consent for&#xD;
             this study.&#xD;
&#xD;
          2. Must be at least 18 years of age&#xD;
&#xD;
          3. Must have a definite clinical diagnosis of moderate to severe facial papulopustular&#xD;
             rosacea&#xD;
&#xD;
          4. Subjects must be willing and able to understand and comply with the requirements of&#xD;
             the study and apply the medication as instructed.&#xD;
&#xD;
          5. Subjects must be in general good health and free from any clinically significant&#xD;
             disease, other than rosacea, that might interfere with the study evaluations.&#xD;
&#xD;
          6. Females of childbearing potential (excluding women who are surgically sterilized&#xD;
             (verified tubal ligation or bilateral oophorectomy or hysterectomy) or post-&#xD;
             menopausal for at least 2 years), in addition to having a negative urine pregnancy&#xD;
             test at Visit 1/Day 1 (Baseline), must be willing to use an acceptable form of birth&#xD;
             control during the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects, who are pregnant, breastfeeding, or planning a pregnancy within the period&#xD;
             of their study participation.&#xD;
&#xD;
          2. Current or past ocular rosacea.&#xD;
&#xD;
          3. Presence of any other facial skin condition that might interfere with rosacea&#xD;
             diagnosis and/or assessment.&#xD;
&#xD;
          4. History of hypersensitivity or allergy to the study medication and/or any ingredient&#xD;
             in the study medication.&#xD;
&#xD;
          5. Use of radiation therapy and/or anti-neoplastic agents within 90 days prior to Visit&#xD;
             1/Day 1 (Baseline).&#xD;
&#xD;
          6. Current use of anticoagulation therapy and use throughout the study.&#xD;
&#xD;
          7. Use of medicated make-up (including anti-aging make-up) throughout the study&#xD;
&#xD;
          8. Use during the study of 1) systemic steroids, 2) topical retinoids to the face 3)&#xD;
             antibiotics known to impact rosacea 4) immunosuppressive agents, or immunomodulators).&#xD;
&#xD;
          9. Facial use of 1) topical steroids, 2) topical anti-inflammatory agents, 3) topical&#xD;
             antimycotics, 4) any topical rosacea treatments or 4) topical antibiotics.&#xD;
&#xD;
         10. Use of medicated cleansers on the face (throughout the study.&#xD;
&#xD;
         11. Subject consumes excessive alcohol, abuses drugs, or has a condition that could&#xD;
             compromise the subject's ability to comply with study requirements&#xD;
&#xD;
         12. Use of topical astringents or abrasives, medicated topical preparations (prescription&#xD;
             and OTC products) within 2 days prior to Visit 1 and throughout the study.&#xD;
&#xD;
         13. Use of antipruritics (including antihistamines), spa treatments or chlorine exposure&#xD;
             (swimming etc.) within 24 hours of all study visits.&#xD;
&#xD;
         14. Participation in any clinical study involving an investigational product, agent or&#xD;
             device that might influence the intended effects or mask the side effects of study&#xD;
             medication in the 1 month (30 days) prior Visit 1/Day 1 (Baseline) or throughout the&#xD;
             study.&#xD;
&#xD;
         15. Previous enrollment in this study or current enrollment in this study at another&#xD;
             participating site.&#xD;
&#xD;
         16. Use of tanning booths, sun lamps (excessive UV radiation e.g., phototherapy, daily&#xD;
             extended exposure or occupational exposure to the sun), sunbathing or excessive&#xD;
             exposure to the sun 1 week prior to baseline and throughout the study.&#xD;
&#xD;
         17. Subjects who in the opinion of the investigator, are unlikely to be able to follow the&#xD;
             restrictions of the protocol and complete the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 6, 2016</study_first_submitted>
  <study_first_submitted_qc>June 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2016</study_first_posted>
  <results_first_submitted>October 21, 2020</results_first_submitted>
  <results_first_submitted_qc>December 9, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 5, 2021</results_first_posted>
  <disposition_first_submitted>February 19, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>February 19, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">February 22, 2018</disposition_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosacea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivermectin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 27, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/17/NCT02795117/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 27, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/17/NCT02795117/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Test Product</title>
          <description>Ivermectin cream</description>
        </group>
        <group group_id="P2">
          <title>Reference Product</title>
          <description>Ivermectin (reference) cream</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo cream</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="193"/>
                <participants group_id="P2" count="193"/>
                <participants group_id="P3" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="175"/>
                <participants group_id="P2" count="166"/>
                <participants group_id="P3" count="88"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Test Product</title>
          <description>Ivermectin Cream, 1% (Perrigo)</description>
        </group>
        <group group_id="B2">
          <title>Reference Product</title>
          <description>Ivermectin Cream, 1% (reference)</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo cream</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="193"/>
            <count group_id="B2" value="193"/>
            <count group_id="B3" value="100"/>
            <count group_id="B4" value="486"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.9" spread="12.65"/>
                    <measurement group_id="B2" value="51.3" spread="13.61"/>
                    <measurement group_id="B3" value="51.2" spread="14.25"/>
                    <measurement group_id="B4" value="51.5" spread="13.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="141"/>
                    <measurement group_id="B2" value="140"/>
                    <measurement group_id="B3" value="67"/>
                    <measurement group_id="B4" value="348"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="94"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="155"/>
                    <measurement group_id="B2" value="156"/>
                    <measurement group_id="B3" value="81"/>
                    <measurement group_id="B4" value="392"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="188"/>
                    <measurement group_id="B2" value="189"/>
                    <measurement group_id="B3" value="97"/>
                    <measurement group_id="B4" value="474"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Percent Change From Baseline in the Inflammatory (Papules and Pustules) Lesion Count</title>
        <time_frame>Day 1 to Day 84</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Test Product</title>
            <description>Ivermectin cream</description>
          </group>
          <group group_id="O2">
            <title>Reference Product</title>
            <description>Ivermectin (reference) cream</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo cream</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change From Baseline in the Inflammatory (Papules and Pustules) Lesion Count</title>
          <population>Per protocol population</population>
          <units>percentage of lesion reduction</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="147"/>
                <count group_id="O3" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.47" spread="30.222"/>
                    <measurement group_id="O2" value="67.89" spread="30.244"/>
                    <measurement group_id="O3" value="55.51" spread="32.660"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>provides 85% power of success</non_inferiority_desc>
            <param_type>equivalence ratio</param_type>
            <param_value>96.4</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>91.0</ci_lower_limit>
            <ci_upper_limit>105.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects With Clinical Success on the Investigator Global Assessment</title>
        <description>Clinical success is defined as a score of clear or almost clear</description>
        <time_frame>Day 1 to Day 84</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Test Product</title>
            <description>Ivermectin cream</description>
          </group>
          <group group_id="O2">
            <title>Reference Product</title>
            <description>Ivermectin (reference) cream</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo cream</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With Clinical Success on the Investigator Global Assessment</title>
          <description>Clinical success is defined as a score of clear or almost clear</description>
          <population>Per protocol population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="147"/>
                <count group_id="O3" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="79"/>
                    <measurement group_id="O3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>provides 85% power of success</non_inferiority_desc>
            <param_type>Equivalence difference</param_type>
            <param_value>-6.48</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.31</ci_lower_limit>
            <ci_upper_limit>1.85</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 1 to day 84</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Test Product</title>
          <description>Ivermectin cream</description>
        </group>
        <group group_id="E2">
          <title>Reference Product</title>
          <description>Ivermectin (reference) cream</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo cream</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="193"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jonathan Schwartz</name_or_title>
      <organization>Perrigo</organization>
      <phone>718-960-9900</phone>
      <email>jonathan.schwartz@perrigo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

